Clinical and Prognostic Associations Based on Serum Antinuclear Antibodies in Japanese Patients with Systemic Sclerosis
Corresponding Author
Masataka Kuwana MD
Associate in Medicine, Keio University School of Medicine (current address: Research Investigator in Medicine, University of Pittsburgh School of Medicine)
Departments of Medicine, Keio University School of Medicine, Tokyo, and Nippon Kokan Hospital, Kawasaki, Japan.
Kuwana, MD, Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, 985 Scaife Hall, Pittsburgh, PA 15261Search for more papers by this authorJunichi Kaburaki MD
Assistant Professor of Medicine, Keio University School of Medicine
Departments of Medicine, Keio University School of Medicine, Tokyo, and Nippon Kokan Hospital, Kawasaki, Japan.
Search for more papers by this authorYutaka Okano MD
Faculty of Medicine, Nippon Kokan Hospital
Departments of Medicine, Keio University School of Medicine, Tokyo, and Nippon Kokan Hospital, Kawasaki, Japan.
Search for more papers by this authorTakeshi Tojo MD
Assistant Professor of Medicine, Keio University School of Medicine
Departments of Medicine, Keio University School of Medicine, Tokyo, and Nippon Kokan Hospital, Kawasaki, Japan.
Search for more papers by this authorMitsuo Homma MD
Professor of Medicine, Keio University School of Medicine.
Departments of Medicine, Keio University School of Medicine, Tokyo, and Nippon Kokan Hospital, Kawasaki, Japan.
Search for more papers by this authorCorresponding Author
Masataka Kuwana MD
Associate in Medicine, Keio University School of Medicine (current address: Research Investigator in Medicine, University of Pittsburgh School of Medicine)
Departments of Medicine, Keio University School of Medicine, Tokyo, and Nippon Kokan Hospital, Kawasaki, Japan.
Kuwana, MD, Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, 985 Scaife Hall, Pittsburgh, PA 15261Search for more papers by this authorJunichi Kaburaki MD
Assistant Professor of Medicine, Keio University School of Medicine
Departments of Medicine, Keio University School of Medicine, Tokyo, and Nippon Kokan Hospital, Kawasaki, Japan.
Search for more papers by this authorYutaka Okano MD
Faculty of Medicine, Nippon Kokan Hospital
Departments of Medicine, Keio University School of Medicine, Tokyo, and Nippon Kokan Hospital, Kawasaki, Japan.
Search for more papers by this authorTakeshi Tojo MD
Assistant Professor of Medicine, Keio University School of Medicine
Departments of Medicine, Keio University School of Medicine, Tokyo, and Nippon Kokan Hospital, Kawasaki, Japan.
Search for more papers by this authorMitsuo Homma MD
Professor of Medicine, Keio University School of Medicine.
Departments of Medicine, Keio University School of Medicine, Tokyo, and Nippon Kokan Hospital, Kawasaki, Japan.
Search for more papers by this authorAbstract
Objective. To clarify the clinical features and prognosis of systemic sclerosis (SSc) based on serum antinuclear antibodies (ANA).
Methods. We studied 275 consecutive Japanese patients newly diagnosed as having SSc, who were first evaluated during the period 1971—1990. Eight SSc–related ANA were identified using indirect immunofluorescence, double immunodiffusion, or immunoprecipitation assays. Clinical and prognostic features were retrospectively analyzed in patient groups, categorized by their serum ANA.
Results. Cumulative survival rates at 10 years after diagnosis of SSc were 93% in patients with anticentromere antibodies (ACA), 72% in those with anti—U1 RNP, 66% in those with anti—DNA topoisomerase I (anti—topo I), and 30% in those with anti-RNA polymerases I, II, and III (anti-RNAP). Major organ involvement linked to cause of death included biliary cirrhosis in patients with ACA, isolated pulmonary arterial hypertension and cerebral hemorrhage in those with anti—U1 RNP, pulmonary interstitial fibrosis in those with anti—topo I, and cardiac and renal involvement in those with anti-RNAP.
Conclusion. Determinations of serum ANA in SSc patients are useful in predicting organ involvement and long-term outcome.
References
- 1 Medsger TA Jr: Systemic sclerosis (scleroderma), localized forms of scleroderma, and calcinosis, Arthritis and Allied Conditions. Twelfth edition. Edited by DJ McCarty, WJ Koopman. Philadelphia, Lea & Febiger, 1993
- 2 Tan EM: Antinuclear antibodies; diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 44: 93–151, 1989
- 3 Moroi Y, Peebles C, Fritzler MJ, Steigerwald J, Tan EM: Autoantibody to centromere (kinetochore) in scleroderma sera. Proc Natl Acad Sci U S A 77: 1627–1631, 1980
- 4 Douvas AS, Achten M, Tan EM: Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma. J Biol Chem 254: 10514–10522, 1979
- 5 Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR: Mixed connective tissue disease: an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 52: 148–159, 1972
- 6 Reddy R, Tan EM, Henning D, Nogha K, Bush H: Detection of a nucleolar 7-2 ribonucleoprotein and cytoplasmic 8-2 ribonucleoprotein with autoantibodies from patients with scleroderma. J Biol Chem 258: 1383–1386, 1983
- 7 Ochs RL, Lischwe MA, Spohn WH, Bush H: Fibrillarin: a new protein of the nucleolus identified by autoimmune sera. Biol Cell 54: 123–134, 1985
- 8 Mimori T, Akizuki M, Yamagata H, Inada S, Yoshida S, Homma M: Characterization of a high molecular weight acidic nuclear protein recognized by autoantibodies in sera from patients with polymyositis-scleroderma overlap. J Clin Invest 68: 611–620, 1981
- 9 Reichlin M, Maddison PJ, Targoff I, Bunch T, Arnett FC, Sharp GC, Treadwell EL, Tan EM: Antibodies to a nuclear/nucleolar antigen in patients with polymyositis overlap syndrome. J Clin Immunol 4: 40–44, 1984
- 10 Kuwana M, Kaburaki J, Mimori T, Tojo T, Homma M: Autoantibody reactive with three classes of the RNA polymerases in sera from patients with systemic sclerosis. J Clin Invest 91: 1399–1404, 1993
- 11 Okano Y, Steen VD, Medsger TA Jr: Novel human serum autoantibodies reactive with RNA polymerase III: a major autoantigen in systemic sclerosis with diffuse cutancous involvement. Ann Intern Med (in press)
- 12 Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler MJ, Peebles C: Diversity of antinuclear antibodies in progressive systemic sclerosis: anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum 23: 617–625, 1980
- 13 Steen VD, Ziegler GL, Rodnan GP, Medsger TA Jr: Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum 27: 125–131, 1984
- 14 Fritzler MJ, Kinsella TD, Garbutt E: The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med 69: 520–526, 1980
- 15 Okano Y, Medsger TA Jr: Autoantibody to Th ribonucleoprotein (nucleolar 7-2 RNA protein particle) in patients with systemic sclerosis. Arthritis Rheum 33: 1822–1828, 1990
- 16 Kuwana M, Mimori T, Hama N, Kaburaki J, Okano T, Tojo T: Clinical significance of anti-nucleolar antibodies identified by immunoprecipitation assays in sera from patients with systemic sclerosis. Jpn J Rheumatol 4: 265–275, 1993
- 17 Shero JH, Brodwell B, Rothfield NF, Earnshaw WC: High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients. Science 231: 737–740, 1986
- 18 Cattogio LJ, Bernstein RM, Black CM, Hughes GRV, Maddison PJ: Serologic markers in progressive systemic sclerosis: clinical correlations. Ann Rheum Dis 42: 23–27, 1983
- 19 Okano Y, Steen VD, Medsger TA Jr: Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. Arthritis Rheum 35: 95–100, 1992
- 20 Medsger TA Jr, Masi AT: Epidemiology of systemic sclerosis (scleroderma). Ann Intern Med 74: 714–721, 1971
- 21 Rowell NR: The prognosis of systemic sclerosis. Br J Dermatol 95: 57–60, 1976
- 22 Barnett AJ: Scleroderma (progressive systemic sclerosis): prognosis and course based on a personal series of 118 cases. Med J Aust 2: 129–134, 1978
- 23 Kaburaki J, Lee CC, Kuwana M, Tojo T, Ikeda Y, Takano M, Funatsu Y: Initial predictors of survival in patients with systemic sclerosis (scleroderma). Keio J Med 41: 141–145, 1992
- 24 Medsger TA Jr, Masi AT: Survival with scleroderma. II. A life-table analysis of clinical and demographic factors in 358 male US veteran patients. J Chronic Dis 26: 647–660, 1973
- 25 Bennett R, Bluestone R, Holt PJL, Bywaters EGL: Survival in scleroderma. Ann Rheum Dis 30: 581–588, 1971
- 26 Farmer RG, Gifford RW, Hines EA Jr: Prognostic significance of Raynaud's phenomenon and other clinical characteristics of systemic sclerosis. Circulation 21: 1088–1095, 1960
- 27 Tuffanelli DL, Winkelmann RK: Systemic scleroderma: a clinical study of 727 cases. Arch Dermatol 84: 359–371, 1961
- 28 Tuffanelli DL, Winkelmann RK: Diffuse systemic scleroderma: a comparison with acrosclerosis. Ann Intern Med 57: 198–203, 1962
- 29 Barnett AJ, Miller MH, Littlejohn GO: A survival study of patients with scleroderma diagnosed over 30 years (1953–1983): the value of a simple cutaneous classification in the early stages of the disease. J Rheumatol 15: 276–283, 1988
- 30 McCarty GA, Rice JR, Bembe ML, Barada FA Jr: Anticentromere antibody: clinical correlations and association with favorable prognosis in patients with scleroderma variants. Arthritis Rheum 26: 1–7, 1983
- 31 Weiner ES, Earnshaw WC, Senécal J-L, Bordwell B, Johnson P, Rothfield NF: Clinical associations of anticentromere antibodies and antibodies to topoisomerase I: a study of 355 patients. Arthritis Rheum 31: 378–385, 1988
- 32 Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23: 581–590, 1980
- 33 Berg PA, Klein R, Lindeborn-Fotinos J, Kloppel G: ATPase associated antigen (M2): marker antigen for serological diagnosis of primary biliary cirrhosis. Lancet 2: 1423–1425, 1982
- 34 Homma M, Tojo T, Akizuki M, Yamagata H: Criteria for Sjögren's syndrome in Japan. Scand J Rheumatol 15 (suppl 61): 26–27, 1986
- 35 Kuwana M, Kaburaki J, Mimori T, Tojo T, Homma M: Autoantigenic epitopes on DNA topoisomerase I: clinical and immunogenetic associations in systemic sclerosis. Arthritis Rheum 36: 1406–1413, 1993
- 36 Lerner MR, Steitz JA: Antibodies to small nuclear RNAs complexed with proteins are produced by patients with systemic lupus erythematosus. Proc Natl Acad Sci U S A 76: 5495–5499, 1979
- 37 Goto T, Laipis P, Wang JC: The purification and characterization of DNA topoisomerase I and II of the yeast Saccharomyces cerevisiae. J Biol Chem 259: 10422–10429, 1984
- 38 Steen VD, Powell DL, Medsger TA Jr: Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 31: 196–203, 1988
- 39 Farrell DA, Medsger TA Jr: Trigeminal neuropathy in progressive systemic sclerosis. Am J Med 73: 57–62, 1982
- 40 Bernstein RM, Callender ME, Neubergaer JM, Hughes GRV, Williams R: Anticentromere antibody in primary biliary cirrhosis. Ann Rheum Dis 41: 612–614, 1982
- 41 Makinen D, Fritzler M, Davis P, Sherlock S: Anticentromere antibodies in primary biliary cirrhosis. Arthritis Rheum 26: 914–917, 1983
- 42 Salerni R, Rodnan GP, Leon DF, Shaver JA: Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). Ann Intern Med 86: 394–399, 1977
- 43 Young RH, Mark GJ: Pulmonary vascular changes in scleroderma. Am J Med 64: 998–1004, 1978
- 44 Ungerer RG, Tashkin DP, Furst D, Clements PJ, Gong H Jr, Bein M, Smith JW, Roberts N, Cabeen W: Prevalence and clinical correlations of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med 75: 65–74, 1983
- 45 Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA Jr: Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 29: 515–524, 1986
- 46 Sullivan WD, Hurst DJ, Harmon CE, Esther JH, Agia GA, Maltby JD, Gillard SB, Held CN, Wolfe JF, Sunderrajan EV, Maricq HR, Sharp GC: A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease. Medicine (Baltimore) 63: 92–107, 1984
- 47 Oddis CV, Okano Y, Rudert WA, Trucco M, Duquesnoy RJ, Medsger TA Jr: Serum autoantibody to the nucleolar antigen PM-Scl: clinical and immunogenetic associations. Arthritis Rheum 35: 1211–1217, 1992
